Myriad Genetics and Gabbi to Work Together to Increase Access to Hereditary Cancer Risk Assessment Tools

Core Insights - Myriad Genetics, Inc. has announced a collaboration with Gabbi to provide an integrated offering for breast cancer risk assessment and specialist care services [1][2] - The partnership aims to enhance patient access to genetic testing and personalized care plans through Gabbi's telehealth solution and Myriad's MyRisk with RiskScore Hereditary Cancer Test [2][4] Company Overview - Myriad Genetics is a leader in molecular diagnostics testing and precision medicine, focusing on advancing health and well-being through molecular tests that assess disease risk and guide treatment decisions [5] - Gabbi is a telehealth solution designed to empower women in understanding and managing their breast cancer risks, providing immediate access to clinicians and personalized action plans [4][5] Product and Service Details - The MyRisk with RiskScore Hereditary Cancer Test enables 53% of patients to qualify for a medical management change, such as more frequent mammograms or MRI imaging [3] - Gabbi's solution includes logistics and educational support, ensuring a seamless experience for patients identified as high risk [2][4]